Here’s what you should know:
1. Exact Sciences is developing a new product that would test for lung cancer. The company plans to launch a major study of the test by early 2018, according to the State Journal.
2. The company doubled year-over-year earnings in the second quarter. The percentage of completed Cologuard tests rose 150 percent over second quarter fiscal year 2016 figures.
3. The company posted revenues of $57.6 million for the second quarter.
4. Net losses were $30.8 million or $0.27 per share. Exact Sciences reported losses of $44.8 million or $0.46 per share for the same quarter last year.
5. Approximately 81,000 providers have ordered a Cologuard test from its inception through the second quarter of 2017.
6. Concerning rest-of-year outlooks, Exact Sciences anticipates revenues between $230 million and $240 million. The company also expects to complete at least 550,000 tests.
Those estimates are higher than previous guidance, which projected revenues between $195 million and $205 million, with at least 470,000 completed tests.
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — July 17-21
GI leader to know: Dr. J. Craig Davis of GastroArkansas
GI center to know: GastroArkansas
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
